Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 2/20 | 0.55 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.52 |
| ▸ | HSD11B1 | P28845 | 7/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | PARP1 | P09874 | 3/20 | 0.49 |
| ▸ | BTK | Q06187 | 1/20 | 0.48 |
| ▸ | NAMPT | P43490 | 1/20 | 0.47 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.44 |
| ▸ | CKS1B | P61024 | 1/20 | 0.44 |
| ▸ | SKP1 | P63208 | 1/20 | 0.44 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30599928 | 0.91 | HSD11B1 (0.60) | CTSKEPHX1HSD11B1CYP2C9CA1 | |
| SCHEMBL6584897 | 0.88 | DRD2 (0.51) | CTSKEPHX1HSD11B1CYP2C9CA1 | |
| SCHEMBL2223544 | 0.88 | CA1 (0.54) | CTSKEPHX1HSD11B1CYP2C9CA1 | |
| SCHEMBL17222576 | 0.88 | CTSK (0.52) | CTSKEPHX1HSD11B1CYP2C9CA1 | |
| SCHEMBL6187601 | 0.85 | CTSK (0.56) | CTSKEPHX1HSD11B1CYP2C9CA1 | |
| SCHEMBL18926997 | 0.85 | EPHX1 (0.70) | CTSKEPHX1HSD11B1CYP2C9CA1 | |
| SCHEMBL27408850 | 0.85 | CTSK (0.56) | CTSKEPHX1HSD11B1CYP2C9CA1 | |
| SCHEMBL89460 | 0.85 | EPHX2 (0.56) | CTSKEPHX1HSD11B1CYP2C9CA1 | |
| SCHEMBL15297472 | 0.84 | CTSK (0.52) | CTSKEPHX1HSD11B1CYP2C9CA1 | |
| SCHEMBL14679328 | 0.84 | CTSK (0.55) | CTSKEPHX1HSD11B1CYP2C9CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106188027-B | Aromatic heterocyclic derivative and application thereof in medicine | 广东东阳光药业有限公司 | 2020-10-20 | — | — | CN | disclosed |
| US-7709497-B2 | Pyrazolo[3,4-b]pyridine compound, and its use as a PDE4 inhibitor | GLAXO GROUP LIMITED (GB) | 2010-05-04 | — | — | US | disclosed |
| US-7709497-B2 | Pyrazolo[3,4-b]pyridine compound, and its use as a PDE4 inhibitor | GLAXO GROUP LIMITED (GB) | 2010-05-04 | — | — | US | disclosed |
| US-20080275078-A1 | Pyrazolo[3,4-B] Pyridine Compounds and Their Use as Pde4 Inhibitors | GLAXO GROUP LIMITED (GB) | 2008-11-06 | — | — | US | disclosed |
| US-20080275078-A1 | Pyrazolo[3,4-B] Pyridine Compounds and Their Use as Pde4 Inhibitors | GLAXO GROUP LIMITED (GB) | 2008-11-06 | — | — | US | disclosed |
| US-20080132536-A1 | PYRAZOLO [3,4-B] PYRIDINE COMPOUNDS, AND THEIR USE AS PDE4 INHIBITORS | GLAXO GROUP LIMITED | 2008-06-05 | — | — | US | disclosed |
| US-20080132536-A1 | PYRAZOLO [3,4-B] PYRIDINE COMPOUNDS, AND THEIR USE AS PDE4 INHIBITORS | GLAXO GROUP LIMITED | 2008-06-05 | — | — | US | disclosed |
| US-20070280971-A1 | Pyrazolo[3,4-B]Pyridine Compound, and Its Use as a Pde4 Inhibitor | GLAXO GROUP LIMITED (GB) | 2007-12-06 | — | — | US | disclosed |
| US-20070280971-A1 | Pyrazolo[3,4-B]Pyridine Compound, and Its Use as a Pde4 Inhibitor | GLAXO GROUP LIMITED (GB) | 2007-12-06 | — | — | US | disclosed |
| US-20070111995-A1 | Pyrazolo [3,4-B] pyridine Compounds and Their Use as Phosphodiesterase Inhibitors | GLAXO GROUP LIMITED (GB) | 2007-05-17 | — | — | US | disclosed |
| US-20070111995-A1 | Pyrazolo [3,4-B] pyridine Compounds and Their Use as Phosphodiesterase Inhibitors | GLAXO GROUP LIMITED (GB) | 2007-05-17 | — | — | US | disclosed |
| WO-2005090352-A1 | PYRAZOLO[3,4-B]PYRIDINE COMPOUND, AND ITS USE AS A PDE4 INHIBITOR | GLAXO GROUP LIMITED (GB) | 2005-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132536-A1 | PYRAZOLO [3,4-B] PYRIDINE COMPOUNDS, AND THEIR USE AS PDE4 INHIBITORS | PDE4A, PDE4B, PDE4C | CTSK 1224/4885EPHX1 117/4885HSD11B1 77/4885 |
| US-20070111995-A1 | Pyrazolo [3,4-B] pyridine Compounds and Their Use as Phosphodiesterase Inhibitors | PDE4B, PDE3B, PDE4A | CTSK 2364/4885EPHX1 695/4885HSD11B1 111/4885 |
| US-20080275078-A1 | Pyrazolo[3,4-B] Pyridine Compounds and Their Use as Pde4 Inhibitors | PDE4B, PDE3B, PDE4A | CTSK 2261/4885EPHX1 715/4885HSD11B1 71/4885 |
| US-20070280971-A1 | Pyrazolo[3,4-B]Pyridine Compound, and Its Use as a Pde4 Inhibitor | PDE4B, PDE4A, PDE3B | CTSK 3049/4885EPHX1 1379/4885HSD11B1 215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.